MedAbome

Executive Summary

MedAbome, Inc. is a preclinical-stage biotechnology company pioneering next-generation therapeutic antibodies for oncology and immune-mediated diseases. Founded in 2020 and headquartered in San Francisco with operations in Israel, the company leverages proprietary live-cell immunization and high-throughput screening platforms to discover antibodies targeting conformational epitopes. These platforms enable the development of first-in-class antibodies, antibody-drug conjugates (ADCs), and CAR-T/NK cell therapies with enhanced specificity and efficacy. By focusing on disease-specific conformational epitopes, MedAbome aims to overcome limitations of conventional antibody discovery, potentially unlocking novel targets in solid tumors and autoimmune conditions. The company's platform-driven approach positions it as a versatile player in the growing antibody therapeutics market, though its preclinical stage means clinical validation remains ahead. Despite its innovative technology, MedAbome faces typical early-stage risks, including the need for substantial capital to advance programs through IND-enabling studies and into the clinic. The company has not disclosed total funding or valuation, suggesting it may be in stealth mode or early in its fundraising journey. Near-term catalysts include preclinical data readouts that could attract partnerships or Series A financing, but the timeline to clinical trials is likely several years away. The competitive landscape includes established antibody platforms, yet MedAbome's focus on conformational epitopes and multi-modality capabilities could differentiate it if data prove compelling. Conviction is tempered by the lack of disclosed funding and preclinical validation, but the platform's potential warrants monitoring.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data presentation at major oncology conference40% success
• Q4 2026Series A financing round50% success
• H2 2026Partnership or licensing deal for platform technology30% success